Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics

Product Code BCC00003
Publication Date March 2010
Publisher BCC Research
Product Type Report
Pages 374
ISBN Number not applicable
Change currency
PDF £3,065.00 €3,691 $4,847 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics

This Report:

  • Discussion of Treatment Options, Key Products and New Developments in Therapies for Such Genetic Disorders as Cystic Fibrosis, Gaucher Disease, Hemophilia, Huntington' S Disease, Sickle-Cell Disease, and Tay-Sachs Disease
  • Analysis of The Market, Citing Data for 2008, Estimates for 2009, and Projections, with 5-Year Compound Annual Growth Rates (Cagrs), through 2014
  • Examination of The Market in Chromosomal Disorders, Such as down, Klinefelter' S, Prader-Willi, and Turner' S Syndromes
  • Patent Evaluations and Company Profiles.

Study Goals and Objectives

The Goal of The Study, New Developments in Treating Genetic Disorders: The Global Market, Is to Provide An Overview of A Range of Genetic Disorders, Both Mutation and Chromosomal in Nature, and Provide Market Summaries and New Research and Developments. The Market Is Discussed for The 2009 Year and Forecasts Are Provided through 2014. Product Descriptions, Discussions of New Research, and Company Profiles Are Also Provided.

The Study Also Covers Issues Affecting The Current and Forecasted Market, Patent Information, and A List of Key Organizations Covering Genetic Disorders.

Reasons for Doing The Study

Treating Genetic Disorders Has Become One of The Most Complicated Areas of Medicine and There Are Several Thousand Disorders Resulting from Gene Mutations and Chromosomal Malfunctions. Scientists Have Studied These Disorders for Decades; However, There Remain Only A Limited Number of Disorders with Available Treatments. The Demand for New Development Is Strong with Biopharmaceutical Companies, Governments, Private Organizations, and Universities Actively Seeking New Treatments. Several New Developments Have Emerged over The past Few Years Resulting in Markets worth Billions of Dollars. This Study Will Explore Research and Development in Several Select Areas of Genetic Disorders and Discuss The Current and Potential Market Growth.

Scope of Report

This BCC Research Report Is Designed to Be A Helpful Business Tool That Provides A Thorough Evaluation of The Market for A Number of Genetic Disorders, Including Prevalence and Incidence; Biopharmaceutical Treatments; and Research and Development Activities. The Geographic Scope of This Study Is Worldwide.
The Report Covers A Range of Genetic Disorders, Specifically Including:

  • Cystic Fibrosis
  • Fabry Disease
  • Gaucher' S Disease
  • Hemophilia
  • Huntington' S Disease
  • Hunter Syndrome
  • Hurler Syndrome
  • Klinefelter Syndrome
  • Maroteaux - Lamy Syndrome
  • Phenylketonuria (Pku)Prader - Willi Syndrome
  • Pompe Diseaseturner' S Syndrome

Each Market Segment Discussion Provides Detailed Information Based on Current Product Availability, Uses of Products, Forecasts, and Competitive Analyses. Additionally, The Study Covers Some of The Most Significant Issues, Trends and Market Factors.

Methodology

The Information for This BCC Report Was Obtained through Primary and Secondary Data Collection Methods. Primary Methods Included Interviews with Key Representatives in The Industry: Product Development Managers, Clinical Specialists, Research Specialists, Government Departments, and Other Key Representatives Involved in The Genetic Disorder Industry. Secondary Methods Included Published Literature, Investment Reports, Company Literature, and Various Business Journals That Cover Genetic Diseases and Their Products, New Technologies and Related Information.

Market Data for This Report Pertains to The Worldwide Market. All Information Is Displayed Using U.S. Dollars at The Manufacturers' Level. The Base Year of The Report Is 2009, with Historical Data Provided for 2007 and 2008, and Forecast Data Provided through 2014. Historical, Base Year, and Forecast Data Are Provided for Each Market Segment of The Report. Compound Annual Growth Rates Are Determined through A Compilation of Data, Including past Trends, Future Trends, Demographics, Incidence, Mortality, Products in Research and Development, Current Product Growth, and Other Trends. Competitor Market Share Estimates Are Provided for Each Market Segment for The 2009 Base Year with A Forecast through 2014.

Analyst Credentials

Melissa Elder Is An Experienced Healthcare Market Analyst, Specializing in Prescription and over - The - Counter Pharmaceuticals, Medical Devices, Animal Health Products, and Emerging Healthcare Technologies. Ms. Elder Has More than 13 Years of Experience in The Healthcare Industry, Specializing in Market Research for The past 10 Years. This Experience Has Given Her Substantial Insight into Pharmaceutical Market Analysis. Her Work in The Medical Community, Including Emergency Room Medical Training and Healthcare Information System Coordination, Has Enhanced Her Ability to Provide Insight into Many Healthcare Markets.

Contents

  • Chapter- 1: Introduction -- Complimentary
    • Study Goals and Objectives
    • Reasons for Doing The Study
    • Scope of Report
    • Methodology
    • Analyst Credentials
    • Related BCC Studies
    • BCC Online Services
    • Disclaimer
  • Chapter-2: Summary
    • Genetic Disorder Markets: Major Markets Summary
    • Summary Table A Global Genetic Disorder Product Revenues by Major Market Segment, through 2014 ($ Millions)
    • Summary Figure Global Genetic Disorder Product Revenues, 2007-2014 ($ Millions)
    • Leading Manufacturers
    • Summary Table B Total Company Sales for Genetic Disorder Treatment, 2009 ($ Millions)
  • Chapter-3: Industry Overview
    • Introduction
    • History of Genetic Research
    • Overview of DNA and Genes
    • The Human Genome Project
    • Hapmap Project
    • Terminology
    • Table 1 Glossary of Genetic Terms
    • Genes and Family History
    • Overview of Genetic Disorders
    • Gene Mutations
    • Causes of Gene Mutations
    • Genetic Testing and Screening
    • Testing Population Groups (Ethnogenetics)
    • Direct to Consumer Genetic Testing
    • U.S. Demographics
    • Table 2 Number of Births in The U.S., 2006-2010
    • Table 3 Population Growth and Birth Statistics U.S., 2011-2020 (Thousands)
    • Figure 1 Population Growth and Birth Statistics U.S. 2011-2020 (Thousands)
    • International Demographics
    • Table 4 Estimated World Population and Annual Growth by Selected Age Group and Selected Years, 2000 through 2030 (Millions)
    • Figure 2 Estimated World Population by Selected Age Group and Selected Years, 2000-2030 (Millions)
    • Table 5 World Population by Selected Countries, through 2014 (Millions)
    • Figure 3 World Population by Selected Countries, 2007-2014 (Millions)
    • International Birth Rate Statistics
    • Table 6 Births for Selected Countries, 1995-2015 (Thousands)
    • Figure 4 Births for Selected Countries, 1995-2015 (Thousands)
  • Chapter-4: Issues Affecting The Market
    • Genetic Research
    • Gene Therapy Compared to Cell Therapy
    • Issues with Human Cloning
    • Legistlative Issues
    • The Genetic Information Nondiscrimination Act (Gina)
    • German Legislation
    • Australian Genetic Testing Law
    • European Union Action in The Field of Rare Diseases
    • Genetics Clinics
    • Table 7 Number of Genetic Clinics by Country
    • Genome Sequencing Technology
    • Technological Applications of Genome Sequencing
    • Sequencing Costs
  • Chapter-5: Gene Mutation Disorders
    • Descriptions of Gene Mutation Disorders
    • Cystic Fibrosis
    • Treatment Options
    • Key Products
    • Table 8 Pharmaceutical Treatments for Cystic Fibrosis
    • New Developments
    • New Developments (Continued)
    • Table 9 Cystic Fibrosis Developments by Phase of Development
    • Table 9 (Continued)
    • Fabry Disease
    • Treatment Options
    • Key Products
    • Table 10 Pharmaceutical Treatments for Fabry Disease
    • New Developments
    • Table 11 Fabry Disease Developments by Phase of Development
    • Gaucher' S Disease
    • Treatment Options
    • Key Products
    • Table 12 Pharmaceutical Treatments for Gaucher' S Disease
    • New Developments
    • Table 13 Gaucher' S Disease Developments by Phase of Development
    • Hemophilia and Other Inherited Bleeding Disorders
    • Treatment Options
    • Key Products
    • Key Products (Continued)
    • Table 14 Biological and Pharmaceutical Treatments for Hemophilia and Others
    • Table 15 Expanded Indications and Product Changes 2005-2009
    • New Developments
    • Table 16 Hemophilia and Related Blood Disorder Developments by Phase of Development
    • Huntington' S Disease
    • Treatment Options
    • Key Products
    • Table 17 Pharmaceutical Treatments for Huntington' S Disease
    • New Developments
    • Table 18 Huntington' S Disease Developments by Phase of Development
    • Hunter Syndrome
    • Treatment Options
    • Key Products
    • Table 19 Pharmaceutical Treatments for Hunter Syndrome
    • New Developments
    • Table 20 Hunter Syndrome Developments by Phase of Development
    • Hurler Syndrome
    • Treatment Options
    • Key Products
    • Table 21 Pharmaceutical Treatments for Hurler Syndrome
    • New Developments
    • Maroteaux - Lamy Syndrome
    • Treatment Options
    • Key Products
    • Table 22 Pharmaceutical Treatments for Maroteaux - Lamy Syndrome
    • Phenylketonuria (Pku)
    • Treatment Options
    • Key Products
    • Table 23 Pharmaceutical Treatments for Pku
    • New Developments
    • Table 24 Pku Developments by Phase of Development
    • Pompe Disease
    • Treatment Options
    • Key Products
    • Table 25 Pharmaceutical Treatments for Pompe Disease
    • New Developments
    • Table 26 Pompe Disease Developments by Phase of Development
    • Sickle Cell Disease
    • Treatment Options
    • Key Products
    • Table 27 Pharmaceutical Treatments for Sickle Cell Disease
    • New Developments
    • Table 28 Sickle Cell Disease Developments by Phase of Development
    • Tay - Sachs Disease
    • Treatment Options
    • Key Products
    • New Developments
    • Table 29 Tay - Sachs Disease Developments by Phase of Development
    • Wilson' S Disease
    • Treatment Options
    • Key Products
    • Table 30 Pharmaceutical Treatments for Wilson' S Disease
    • New Developments
    • Table 31 Wilson' S Disease Developments by Phase of Development
    • Other Approved Products for Rare Genetic Disorders
    • Other New Development Projects
    • Phase II
    • Phase I
    • Preclinical
    • Muscular Dystrophy Focus: Preclinical through Phase III
    • Avi - 4658
    • Avi - 5038
    • Catena/Sovrima
    • Pro044
    • Ptc - Snt - 317/Omigapil
    • Statistics
    • Cystic Fibrosis
    • Table 32 Cystic Fibrosis Statistics
    • Gaucher' S Disease
    • Table 33 Gaucher' S Disease Statistics
    • Phenylketonuria
    • Tay - Sachs Disease
    • Table 34 Tay - Sachs Disease Statistics
    • Sickle Cell Disease
    • Table 35 Sickle - Cell Disease Statistics
    • Hemophilia
    • Huntington' S Disease
    • Market Size and Growth
    • Table 36 Global Gene Mutation Product Revenues by Disorder through 2014 ($ Millions)
    • Figure 5 Global Gene Mutation Product Revenues by Disorder, 2007-2014 ($ Millions)
    • Competitive Structure and Market Share
    • Cystic Fibrosis Market
    • Table 37 Global Product Revenues for Cystic Fibrosis Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 6 Global Product Revenues for Cystic Fibrosis Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Fabry Disease Market
    • Table 38 Global Product Revenues for Fabry Disease Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 7 Global Product Revenues for Fabry Disease Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Gaucher' S Disease Market
    • Table 39 Global Product Revenues for Gaucher' S Disease Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 8 Global Product Revenues for Gaucher' S Disease Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Hemophilia and Related Blood Disorder Market
    • Hemophilia and Related Blood ... (Continued)
    • Table 40 Global Product Revenues for Hemophilia Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 9 Global Product Revenues for Hemophilia Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Huntington' S Disease Market
    • Table 41 Global Product Revenues for Huntington' S Disease Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 10 Global Product Revenues for Huntington' S Disease Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Hunter Syndrome Market
    • Table 42 Global Product Revenues for Hunter Syndrome Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 11 Global Product Revenues for Hunter Syndrome Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Hurler Syndrome Market
    • Table 43 Global Product Revenues for Hurler Syndrome Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 12 Global Product Revenues for Hurler Syndrome Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Maroteaux - Lamy Syndrome Market
    • Table 44 Global Product Revenues for Maroteaux - Lamy Syndrome Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 13 Global Product Revenues for Maroteaux - Lamy Syndrome Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Phenylketonuria (Pku) Market
    • Table 45 Global Product Revenues for Pku Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 14 Global Product Revenues for Pku Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Pompe Disease Market
    • Table 46 Global Product Revenues for Pompe Disease Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 15 Global Product Revenues for Pompe Disease Treatments by Manufacturer, 2007-2014 ($ Millions)
  • Chapter-6: Chromosonal Disorders
    • Descriptions of Chromosonal Disorders
    • down Syndrome
    • Treatment Options
    • New Developments
    • Table 47 down Syndrome Developments by Phase of Development
    • Klinefelter Syndrome
    • Treatment Options
    • Key Products
    • Table 48 Examples of Pharmaceutical Treatments for Klinefelter Syndrome
    • New Developments
    • Table 49 Examples of Testosterone Replacement Developments by Phase of Development
    • Prader - Willi Syndrome
    • Treatment Options
    • Key Products
    • Table 50 Pharmaceutical Treatments for Prader - Willi Syndrome
    • New Developments
    • Turner Syndrome
    • Treatment Options
    • Key Products
    • Table 51 Fda Approved Biopharmaceutical Treatments for Turner' S Syndrome
    • Table 51 (Continued)
    • New Developments
    • Table 52 Turner Syndrome Developments by Phase of Development
    • Statistics
    • down Syndrome
    • Table 53 down Syndrome Risk as A Comparison to Maternal Age
    • Klinefelter Syndrome
    • Prader - Willi Syndrome
    • Turner Syndrome
    • Market Size and Growth
    • Table 54 Global Chromosonal Disorder Product Revenues* by Disorder, through 2014 ($ Millions)
    • Figure 16 Global Chromosonal Disorder Product Revenues by Disorder, 2007-2014 ($ Millions)
    • Competitive Structure and Market Share
    • Klinefelter Syndrome
    • Table 55 Global Product Revenues for Klinefelter Syndrome Treatments, through 2014 ($ Millions)
    • Figure 17 Global Product Revenues for Klinefelter Syndrome Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Prader - Willi Syndrome
    • Table 56 Global Product Revenues* for Prader - Willi Syndrome Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 18 Global Product Revenues for Prader - Willi Syndrome Treatments by Manufacturer, 2007-2014 ($ Millions)
    • Turner' S Syndrome
    • Table 57 Global Product Revenues* for Turner' S Syndrome Treatments by Manufacturer, through 2014 ($ Millions)
    • Figure 19 Global Product Revenues for Turner' S Syndrome Treatments by Manufacturer, 2007-2014 ($ Millions)
  • Chapter-7: Market Summary
    • Total Global Market for Genetic Disorders
    • Table 58 Global Genetic Disorder Product Revenues by Major Market Segment, through 2014 ($ Millions)
    • Figure 20 Global Genetic Disorder Product Revenues by Major Market Segment, 2007-2014 ($ Millions)
    • Total Global Market and Percent Distribution by Selected Genetic Disorder
    • Table 59 Global Genetic Disorder Product Revenues by Disorder through 2014 ($ Millions)
    • Figure 21 Global Genetic Disorder Product Revenues by Disorder, 2007-2014 ($ Millions)
    • Geographical Analysis of Genetic Disorder Treatments
    • Table 60 Global Genetic Disorder Product Revenues by Selected Country, through 2014 ($ Millions)
    • Figure 22 Global Genetic Disorder Product Revenues by Selected Country, 2007-2014 ($ Millions)
    • Major Industry Participants by Product Segment
    • Major Industry Participants ...(Continued)
    • Table 61 Major Industry Participants by Product Segments and Sales Growth, through 2014 ($ Millions)
    • Table 61 (Continued)
  • Chapter-8: Technology
    • Patent Analysis
    • Patents and Genetics
    • Patent Evaluation by Genetic Condition
    • Table 62 Patent Information by Genetic Condition
    • Table 62 (Continued)
    • Table 62 (Continued)
    • Table 62 (Continued)
    • Table 62 (Continued)
    • Figure 23 Percent of Patents by Genetic Condition (%)
    • Figure 23 (Continued)
    • Patent Evaluation by Assignee
    • Table 63 Genetic Patent Assignees
    • Table 63 (Continued)
    • Table 63 (Continued)
    • Bristol - Myers Squibb
    • Eli Lilly
    • G. D. Searle & Co./Monsanto Company
    • Genzyme Corp.
    • Purdue Pharma
    • Sigma - Tau Industrie Farmaceutiche Riunite S.P.A.
    • Transkaryotic Therapies
    • Wyeth
  • Chapter-9: Company Profiles
    • Baxter International, Inc.
    • Table 64 Baxter' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 24 Baxter' S Company Revenues, 2007-2009 ($ Millions)
    • Bayer Ag
    • Table 65 Bayer' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 25 Bayer' S Company Revenues, 2007-2009 ($ Millions)
    • Biomarin Pharmaceutical, Inc.
    • Table 66 Biomarin' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 26 Biomarin' S Company Revenues, 2007-2009 ($ Millions)
    • Cangene Corp.
    • Table 67 Cangene' S Company Revenues, 2007-2009* ($ Millions)
    • Figure 27 Cangene' S Company Revenues, 2007-2009 ($ Millions)
    • Csl Behring (Csl Limited)
    • Table 68 Csl' S Company Revenues, 2007-2009* ($ Millions)
    • Figure 28 Csl' S Company Revenues, 2007-2009 ($ Millions)
    • Eli Lilly
    • Table 69 Eli Lilly' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 29 Eli Lilly' S Company Revenues, 2007-2009 ($ Millions)
    • Endo Pharmaceuticals
    • Table 70 Endo' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 30 Endo' S Company Revenues, 2007-2009 ($ Millions)
    • Genentech Inc.
    • Table 71 Genentech and Roche Company Revenues, 2007-2009 ($ Millions)
    • Figure 31 Genentech and Roche Company Revenues, 2007-2009 ($ Millions)
    • Genzyme
    • Table 72 Genzyme' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 32 Genzyme' S Company Revenues, 2007-2009 ($ Millions)
    • H. Lundbeck A/S
    • Table 73 Lundbeck' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 33 Lundbeck' S Company Revenues, 2007-2009 ($ Millions)
    • Novartis International Ag/Sandoz
    • Novartis International Ag/... (Continued)
    • Table 74 Novartis' Company Revenues, 2007-2009 ($ Millions)
    • Figure 34 Novartis' Company Revenues, 2007-2009 ($ Millions)
    • Novo Nordisk A/S
    • Table 75 Novo Nordisk' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 35 Novo Nordisk' S Company Revenues, 2007-2009 ($ Millions)
    • Pfizer, Inc/Wyeth
    • Table 76 Pfizer' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 36 Pfizer' S Company Revenues, 2007-2009 ($ Millions)
    • Shire Plc
    • Table 77 Shire' S Company Revenues, 2007-2009 ($ Millions)
    • Figure 37 Shire' S Company Revenues, 2007-2009 ($ Millions)
  • Chapter-10: Appendix
  • Appendix I: Companies with Genetic Research Projects
    • Adeona Pharmaceuticals, Inc.
    • Aerovance, Inc.
    • Aldagen, Inc.
    • Amicus Therapeutics, Inc.
    • Aop Orphan Pharmaceuticals Ag
    • Applied Genetic Technologies Corp.
    • Avi Biopharma
    • Avicena Group, Inc.
    • Bayer Schering Pharma Ag
    • Biogen Idec
    • Biomarin Pharmaceutical Inc.
    • Copernicus Therapeutics, Inc
    • Csl Behring
    • Eisai, Inc.
    • Gilead Sciences, Inc.
    • Glaxosmithkline Plc
    • Hollis - Eden Pharmaceuticals, Inc.
    • Inspire Pharmaceuticals, Inc.
    • Ipsen
    • Kalobios Pharmaceuticals, Inc.
    • Lantibio, Inc.
    • Mpex Pharmaceuticals, Inc.
    • Neurosearch A/S
    • Northfield Laboratories, Inc.
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Pharmaxis Ltd
    • Prosensa Holding B.V.
    • Protalix Biotherapeutics
    • Ptc Therapeutics, Inc.
    • Quatrx Pharmaceuticals
    • Regenerx Biopharmaceuticals, Inc.
    • Repros Therapeutics Inc.
    • Santhera Pharmaceuticals Holding Ag
    • Shire Plc
    • Sucampo Pharmaceuticals, Inc.
    • Transave, Inc.
    • Vertex Pharmaceuticals, Inc.
  • Appendix II: Associations and Organizations
    • Angelman Syndrome Foundation, Inc.
    • Canadian Society for Mucopolysaccharide and Related Diseases, Inc.
    • Children Living with Inherited Metabolic Diseases (Climb)
    • Celiac Disease Foundation
    • Celiac Sprue Association
    • Cure Cmd (Congenital Muscular Dystrophy)
    • Cystic Fibrosis Foundation
    • Cystic Fibrosis Research, Inc.
    • Cystic Fibrosis Trust
    • Cystic Fibrosis Worldwide
    • down' S Syndrome Association (UK)
    • Fabry Support & Information Group
    • Gauchers Association (UK)
    • Hide & Seek Foundation for Lysosomal Disease Research
    • Hemophilia Federation of America
    • Huntington' S Association of South Africa Postbox 4640
    • Huntington' S Disease Society of America
    • Huntington Society of Canada
    • International Center for Fabry Disease
    • Instituto De Errores Innatos Del Metabolismo
    • Klinefelter Syndrome & Associates (Ks&a)
    • March of Dimes Birth Defects Foundation
    • Muscular Dystrophy Association
    • Muscular Dystrophy Limited (Australia)
    • Muscular Dystrophy Association of New Zealand, Inc.
    • Muscular Dystrophy Campaign
    • Muscular Dystrophy Canada
    • Muscular Dystrophy Ireland
    • National Foundation for Celiac Awareness (Nfca)
    • National Gaucher' S Foundation
    • National Hemophilia Foundation
    • National Institute of Neurological Disorders and Stroke (Ninds)
    • National Mps Society (Hunter Syndrome)
    • National Mps (Mucopolysaccharidoses/ Mucolipidoses) Society, Inc.
    • National Organization for Rare Disorders (Nord)
    • National Tay - Sachs and Allied Diseases Association, Inc.
    • Prader - Willi Syndrome Association (UK)
    • The Prader - Willi Syndrome Association (USA)
    • Sickle Cell Association
    • Sickle Cell Association of Ontario
    • Sickle Cell Association of Texas Gulf Coast
    • Sickle Cell Disease Association of Piedmont
    • Sickle Cell Disease Foundation of California
    • Society for Muscular Dystrophy Information International
    • Turner' S Syndrome Society
    • Turner Syndrome Support Society (UK)
    • U.S. National Library of Medicine
  • Appendix III: International Locations of Genetic Clinics
    • Argentina
    • Australia
    • Austria
    • Bahrain
    • Belgium
    • Brazil
    • Canada
    • Chile
    • Czech Republic
    • Denmark
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Netherlands
    • New Zealand
    • Portugal
    • Russia
    • Saudi Arabia
    • South Korea
    • Spain
    • Turkey
    • United Kingdom